BCL2L1 and neoplasm: We identified that there was upregulation of BCL-2/BCL-xL prosurvival signaling and p-STAT3 activation in HCC827 cells in adaptive escape against erlotinib, primarily localizing along the peripheral rind of the tumor xenograft as in the TKI evading cells [13].